{"entity":{"id":"nct06566079","kind":"trial","name":"Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ISM6331 in mesothelioma, run by InSilico Medicine Hong Kong Limited, now recruiting.","summary":"Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06566079 by InSilico Medicine Hong Kong Limited, with 160 participants planned, started 2024-12-27 and due to reach its primary completion in 2027-08-31. Interventions recorded: ISM6331.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06566079","url":"https://clinicaltrials.gov/study/NCT06566079"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06566079","phase":"1/2","setting":"A Phase 1/2, Open-Label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors","sponsor":"InSilico Medicine Hong Kong Limited","enrolled":160,"outcomes":[]},"route":"/trials/nct06566079/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"}]}}